24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
FSD Pharma
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:58
Intel VP: "Historically, if we were to miss milestones... we usually just gave exemptions. Saying no is a pretty powerful tool"
13:35
“We’re already living in a world where AI is attacking AI”
13:33
“In many cases the first market should not be America”
13:31
“To get Israel to a more precise position in biotech, we need to educate our people to become better managers”
More stories
Buzz
Most popular
Daily
Weekly
1
“Other countries have air-defense systems, but Israel’s are better”: Arrow 3 lands in Germany as Israel pursues new mega deals
2
Nice puts Actimize up for sale at a $1.5-2 billion price tag
3
Johny Srouji weighs leaving Apple, raising stakes for the Israeli executive who built its silicon program
4
Zafran raises $60 million and doubles valuation as it chooses independence over takeover offers
5
Israeli drone startup Heven hits $1 billion valuation in $100 million round led by IonQ
More news
FSD Pharma
3 stories about FSD Pharma
FSD Pharma’s Acquisition of Therapix Hits a Snag
12.12.18
|
Tzally Greenberg
In October, FSD agreed to buy Therapix for $48 million in stock, but a Tuesday filing by Therapix revealed that the companies have returned to the negotiating table
FSD Pharma Co-Chairman on Where the Cannabis Industry Is Headed
28.11.18
|
Tzally Greenberg
On a visit to Israel, the co-chairman of the company said he believes cannabis research is going to come from Israel and Australia. He expects China to become a significant player in the cannabis market
Canada's FSD Pharma to Acquire Israeli Therapix Biosciences for $48 Million in Stock
23.10.18
|
Lilach Baumer
Clinical-stage Therapix Biosciences develops cannabinoid-based drugs for the treatment of neurological conditions, pain management, and infectious diseases